Global Premature Ejaculation Treatment Market -Analysis, Size, Share, Trends and Forecast, 2016 – 2022


Select Your License Type


samplerequest
makeanenquiry
download



Fig. Global Premature Ejaculation Treatment Market Projection

The global market for premature ejaculation treatment was valued at around USD 1.2 billion in 2015 and is expected to reach USD 2.6 billion by 2022, growing at a CAGR of around 11.6% during the forecast period of 2016 to 2022. Premature ejaculation is uncontrolled ejaculation either before or shortly after sexual penetration. It happens with minimal sexual stimulation and before the person wishes. It may result in unsatisfactory sex for both partners. This can increase the anxiety that may add to the problem. It is one of the most common forms of male sexual dysfunction. It has probably affected every man at some point in his life.

Erectile Ddysfunction (ED) and Premature Eejaculation (PE) are the two most prevalent male sexual dysfunctions. The Global Study of Sexual Attitudes and Behaviors and other sources suggests a global prevalence of PE of approximately 20-30% across all age groups. Chances of sexual dysfunction increases with age, physical inactivity, smoking, diabetes, stress and prostate concerns.

Worldwide approximately 100 million men are estimated to suffer from male sexual dysfunction. Rise in base of population with sexual disorders, changing lifestyle habits such as smoking, and drinking alcohol and increasing stress levels in the men due to the work life are some of the driving factors of this market. In addition, large number of drugs under pipeline for FDA approval and introduction of novel techniques are further expected to boost the market growth in the coming years.

Geographically, North America is the leading contributor to the market and is expected to retain its position during the forecast period due to the presence of large number of geriatric population, and large base of patients with sexual disorders. However, Asia-Pacific market is expected to grow at a faster rate during the forecast period. This is predominantly due to increased healthcare awareness, technological advancements, and growing awareness among the population about the treatment options available in the market.

Companies profiled:

  • Janssen Pharmaceutica N. V. (a pharmaceutical company of Johnson and Johnson)
  • Plethora Solutions Holdings PLC
  • Akorn Pharmaceuticals
  • Absorption Pharmaceuticals
  • Allergan
  • Innovus Pharmaceuticals
  • GlaxoSmithKline
  • Pfizer

Report Highlights:

The report delivers a strategic analysis of the global market for premature ejaculation treatment and growth forecast for the period from 2016 – 2022. The scope of the report includes competitive analysis of various market players who are operating in the market, segmental analysis based on type of medication. It also covers geographical analysis of the market with growth forecast for the period of 2016 – 2022. The Porter’s Five Forces analysis and value chain analysis included in the report provides an insight into market dynamics and industry competition.

Moreover, the report also includes growth strategies and entry barriers to be considered to cater to the exact business opportunities in this market. Additionally, to aid in strategic decision making, the report also includes competitive profiling of leading players, recent developments in the industry and various business strategies adopted by them. This report will help players in global premature ejaculation market to plan and implement their strategies in different market areas such as emerging geographies, and new technologies

1. Scope of the report

1.1 Report description
1.2 Research methodology
1.3 List of abbreviations
1.4 Market segmentation

2 Executive summary
3 Qualitative analysis

3.1 Market overview

3.1.1 Drivers
3.1.2 Restraints

3.2 Porters five forces analysis
3.3 Market share analysis of key players, 2015
3.4 Competitive matrix of the key companies
3.5 Pipeline analysis of drugs

4 Global premature ejaculation market, by type, 2016 - 2022

4.1 Oral therapies

4.1.1 Nonselective serotonin reuptake inhibitor
4.1.2 Selective serotonin reuptake inhibitor

4.2 Topical therapies

5 Global premature ejaculation market, by geography, 2016 - 2022

5.1 North America

5.1.1 Oral therapies

5.1.1.1 Nonselective serotonin reuptake inhibitor
5.1.1.2 Selective serotonin reuptake inhibitor

5.1.2 Topical therapies

5.2 Europe

5.2.1 Oral therapies

5.2.1.1 Nonselective serotonin reuptake inhibitor
5.2.1.2 Selective serotonin reuptake inhibitor

5.2.2 Topical therapies

5.3 APAC

5.3.1 Oral therapies

5.3.1.1 Nonselective serotonin reuptake inhibitor
5.3.1.2 Selective serotonin reuptake inhibitor

5.3.2 Topical therapies

5.4 Rest of the World

5.4.1 Oral therapies

5.4.1.1 Nonselective serotonin reuptake inhibitor
5.4.1.2 Selective serotonin reuptake inhibitor

5.4.2 Topical therapies

6 Company profiles

6.1 Janssen Pharmaceutica N. V. (a pharmaceutical company of Johnson and Johnson)
6.2 Plethora Solutions Holdings PLC
6.3 Akorn Pharmaceuticals
6.4 Absorption Pharmaceuticals
6.5 Allergan
6.6 Innovus Pharmaceuticals
6.7 GlaxoSmithKline
6.8 Pfizer


Got a Question?

If you have a question to ask our analyst, just fill this form and send it across, our representative will get in touch with you shortly.